Prasanti A Kotta, Lakshmi Uppalapati, Madhivanan Elango, Jeffrey Triska, Mourad H Senussi
{"title":"Resuscitative Mean Arterial Pressure Targets in Cardiovascular Disease: A Narrative Review of Clinical Outcomes.","authors":"Prasanti A Kotta, Lakshmi Uppalapati, Madhivanan Elango, Jeffrey Triska, Mourad H Senussi","doi":"10.1007/s10557-025-07738-6","DOIUrl":null,"url":null,"abstract":"<p><p>Mean arterial pressure (MAP) is a commonly used hemodynamic proxy for tissue perfusion. Continuous MAP monitoring and maintenance of MAP targets remains a cornerstone for managing shock states. However, co-morbidities and individual variations can complicate the relationship between MAP and organ perfusion. Factors such as fluid balance, microvascular circulation, and endothelial function all influence tissue perfusion. This review examines the nuances of MAP management across various patient populations with cardiovascular disease, including acute myocardial infarction cardiogenic shock, non-acute myocardial infarction cardiogenic shock, cardiac arrest, and cardiac surgery. We discuss the importance of individualized MAP targets, considering underlying health conditions, clinical scenarios, and individual shock physiology. Additionally, the importance of monitoring end-organ autoregulation and perfusion is emphasized to optimize shock management. We discuss a limited body of literature which indicates that higher MAPs are associated with improved outcomes in patients with cardiogenic shock, post-cardiac arrest, and after cardiac surgery. However, owing to the post-hoc and retrospective nature of most of these studies, whether higher MAPs truly lead to improved clinical outcomes or whether patients with higher MAPs are inherently less sick and therefore more likely to have better outcomes cannot be discerned from the available data. Further research, particularly prospective RCTs, is essential to define MAP targets that may improve outcomes across different patient populations and clinical settings.</p>","PeriodicalId":9557,"journal":{"name":"Cardiovascular Drugs and Therapy","volume":" ","pages":""},"PeriodicalIF":3.1000,"publicationDate":"2025-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cardiovascular Drugs and Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s10557-025-07738-6","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0
Abstract
Mean arterial pressure (MAP) is a commonly used hemodynamic proxy for tissue perfusion. Continuous MAP monitoring and maintenance of MAP targets remains a cornerstone for managing shock states. However, co-morbidities and individual variations can complicate the relationship between MAP and organ perfusion. Factors such as fluid balance, microvascular circulation, and endothelial function all influence tissue perfusion. This review examines the nuances of MAP management across various patient populations with cardiovascular disease, including acute myocardial infarction cardiogenic shock, non-acute myocardial infarction cardiogenic shock, cardiac arrest, and cardiac surgery. We discuss the importance of individualized MAP targets, considering underlying health conditions, clinical scenarios, and individual shock physiology. Additionally, the importance of monitoring end-organ autoregulation and perfusion is emphasized to optimize shock management. We discuss a limited body of literature which indicates that higher MAPs are associated with improved outcomes in patients with cardiogenic shock, post-cardiac arrest, and after cardiac surgery. However, owing to the post-hoc and retrospective nature of most of these studies, whether higher MAPs truly lead to improved clinical outcomes or whether patients with higher MAPs are inherently less sick and therefore more likely to have better outcomes cannot be discerned from the available data. Further research, particularly prospective RCTs, is essential to define MAP targets that may improve outcomes across different patient populations and clinical settings.
期刊介绍:
Designed to objectively cover the process of bench to bedside development of cardiovascular drug, device and cell therapy, and to bring you the information you need most in a timely and useful format, Cardiovascular Drugs and Therapy takes a fresh and energetic look at advances in this dynamic field.
Homing in on the most exciting work being done on new therapeutic agents, Cardiovascular Drugs and Therapy focusses on developments in atherosclerosis, hyperlipidemia, diabetes, ischemic syndromes and arrhythmias. The Journal is an authoritative source of current and relevant information that is indispensable for basic and clinical investigators aiming for novel, breakthrough research as well as for cardiologists seeking to best serve their patients.
Providing you with a single, concise reference tool acknowledged to be among the finest in the world, Cardiovascular Drugs and Therapy is listed in Web of Science and PubMed/Medline among other abstracting and indexing services. The regular articles and frequent special topical issues equip you with an up-to-date source defined by the need for accurate information on an ever-evolving field. Cardiovascular Drugs and Therapy is a careful and accurate guide through the maze of new products and therapies which furnishes you with the details on cardiovascular pharmacology that you will refer to time and time again.